SK13242000A3 - Vyhľadávanie a návrh ligandov röntgenovou kryštalografiou - Google Patents

Vyhľadávanie a návrh ligandov röntgenovou kryštalografiou Download PDF

Info

Publication number: SK13242000A3
Authority: SK; Slovakia
Prior art keywords: ligand; target; crystal; biomolecule; compound
Prior art date: 1998-03-06

Application number

SK1324-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Vicki L. Nienaber

Jonathan Greer

Celerino Abad-Zapatero

Daniel W. Norbeck

Original Assignee

Abbott Laboratories

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-06

Filing date

1999-03-05

Publication date

2001-03-12

1999-03-05 Application filed by Abbott Laboratories filed Critical Abbott Laboratories

2001-03-12 Publication of SK13242000A3 publication Critical patent/SK13242000A3/sk

Links

239000003446 ligand Substances 0.000 title claims abstract description 143
238000012216 screening Methods 0.000 title claims description 28
238000013461 design Methods 0.000 title abstract description 13
238000002424 x-ray crystallography Methods 0.000 title abstract description 7
150000001875 compounds Chemical class 0.000 claims abstract description 157
239000013078 crystal Substances 0.000 claims abstract description 106
238000000034 method Methods 0.000 claims abstract description 88
238000012360 testing method Methods 0.000 claims abstract description 20
238000002791 soaking Methods 0.000 claims abstract description 12
230000000593 degrading effect Effects 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims description 72
108090000765 processed proteins & peptides Proteins 0.000 claims description 13
102000004196 processed proteins & peptides Human genes 0.000 claims description 8
229920001184 polypeptide Polymers 0.000 claims description 7
238000002288 cocrystallisation Methods 0.000 claims description 4
238000002441 X-ray diffraction Methods 0.000 claims description 3
230000015572 biosynthetic process Effects 0.000 claims description 3
230000015556 catabolic process Effects 0.000 claims description 2
238000006731 degradation reaction Methods 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims 1
230000001131 transforming effect Effects 0.000 claims 1
230000004071 biological effect Effects 0.000 abstract description 11
230000008569 process Effects 0.000 abstract description 5
230000027455 binding Effects 0.000 description 63
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 39
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 31
229960005356 urokinase Drugs 0.000 description 31
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 29
108090000623 proteins and genes Proteins 0.000 description 27
102000004169 proteins and genes Human genes 0.000 description 24
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
235000018102 proteins Nutrition 0.000 description 22
210000004027 cell Anatomy 0.000 description 21
238000003752 polymerase chain reaction Methods 0.000 description 21
239000000243 solution Substances 0.000 description 16
239000003112 inhibitor Substances 0.000 description 14
239000000872 buffer Substances 0.000 description 13
238000002474 experimental method Methods 0.000 description 13
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
238000002050 diffraction method Methods 0.000 description 11
239000011780 sodium chloride Substances 0.000 description 11
102000004190 Enzymes Human genes 0.000 description 10
238000002425 crystallisation Methods 0.000 description 10
230000008025 crystallization Effects 0.000 description 10
229940079593 drug Drugs 0.000 description 10
239000003814 drug Substances 0.000 description 10
229940088598 enzyme Drugs 0.000 description 10
239000013615 primer Substances 0.000 description 10
108090000790 Enzymes Proteins 0.000 description 9
150000007942 carboxylates Chemical group 0.000 description 9
230000000694 effects Effects 0.000 description 9
239000012634 fragment Substances 0.000 description 9
239000000047 product Substances 0.000 description 9
230000035945 sensitivity Effects 0.000 description 9
IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 8
238000001514 detection method Methods 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
241000235648 Pichia Species 0.000 description 6
239000007983 Tris buffer Substances 0.000 description 6
238000002447 crystallographic data Methods 0.000 description 6
238000013480 data collection Methods 0.000 description 6
229910052739 hydrogen Inorganic materials 0.000 description 6
239000001257 hydrogen Substances 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
239000006166 lysate Substances 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
239000003960 organic solvent Substances 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
239000013598 vector Substances 0.000 description 6
108010059993 Vancomycin Proteins 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
239000011324 bead Substances 0.000 description 5
-1 ester chloride Chemical class 0.000 description 5
239000013604 expression vector Substances 0.000 description 5
238000003384 imaging method Methods 0.000 description 5
239000012528 membrane Substances 0.000 description 5
238000012900 molecular simulation Methods 0.000 description 5
230000010355 oscillation Effects 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
239000002904 solvent Substances 0.000 description 5
239000000758 substrate Substances 0.000 description 5
229960003165 vancomycin Drugs 0.000 description 5
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 5
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 5
229910052725 zinc Inorganic materials 0.000 description 5
ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 4
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
241000700605 Viruses Species 0.000 description 4
238000004364 calculation method Methods 0.000 description 4
238000001444 catalytic combustion detection Methods 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000009792 diffusion process Methods 0.000 description 4
238000009510 drug design Methods 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
239000002773 nucleotide Substances 0.000 description 4
125000003729 nucleotide group Chemical group 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
229910052710 silicon Inorganic materials 0.000 description 4
239000010703 silicon Substances 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
239000011701 zinc Substances 0.000 description 4
UFVLIVCXTIGACT-UHFFFAOYSA-N 2-aminoquinolin-8-ol Chemical compound C1=CC=C(O)C2=NC(N)=CC=C21 UFVLIVCXTIGACT-UHFFFAOYSA-N 0.000 description 3
229930024421 Adenine Natural products 0.000 description 3
239000003155 DNA primer Substances 0.000 description 3
238000001712 DNA sequencing Methods 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
102000005741 Metalloproteases Human genes 0.000 description 3
108010006035 Metalloproteases Proteins 0.000 description 3
101150023810 PHO1 gene Proteins 0.000 description 3
101100271429 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ATP6 gene Proteins 0.000 description 3
101100115751 Trypanosoma brucei brucei dnaaf11 gene Proteins 0.000 description 3
238000005162 X-ray Laue diffraction Methods 0.000 description 3
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
229960000643 adenine Drugs 0.000 description 3
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
229910052921 ammonium sulfate Inorganic materials 0.000 description 3
235000011130 ammonium sulphate Nutrition 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000010367 cloning Methods 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 3
150000002611 lead compounds Chemical class 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000012460 protein solution Substances 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
230000028327 secretion Effects 0.000 description 3
150000003573 thiols Chemical class 0.000 description 3
ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
229940127007 Compound 39 Drugs 0.000 description 2
DEFJQIDDEAULHB-QWWZWVQMSA-N D-alanyl-D-alanine Chemical group C[C@@H]([NH3+])C(=O)N[C@H](C)C([O-])=O DEFJQIDDEAULHB-QWWZWVQMSA-N 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
DEFJQIDDEAULHB-UHFFFAOYSA-N N-D-alanyl-D-alanine Natural products CC(N)C(=O)NC(C)C(O)=O DEFJQIDDEAULHB-UHFFFAOYSA-N 0.000 description 2
102000013566 Plasminogen Human genes 0.000 description 2
108010051456 Plasminogen Proteins 0.000 description 2
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
102000012479 Serine Proteases Human genes 0.000 description 2
108010022999 Serine Proteases Proteins 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
238000007792 addition Methods 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
108010056243 alanylalanine Proteins 0.000 description 2
150000001409 amidines Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000013459 approach Methods 0.000 description 2
238000003556 assay Methods 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
238000004140 cleaning Methods 0.000 description 2
239000006184 cosolvent Substances 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
230000007423 decrease Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
101150098537 kdsB gene Proteins 0.000 description 2
238000002372 labelling Methods 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
238000013507 mapping Methods 0.000 description 2
229960004452 methionine Drugs 0.000 description 2
230000011987 methylation Effects 0.000 description 2
238000007069 methylation reaction Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
150000002894 organic compounds Chemical class 0.000 description 2
229940012957 plasmin Drugs 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000006337 proteolytic cleavage Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000012546 transfer Methods 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
238000007805 zymography Methods 0.000 description 2
UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
DGYWXYFLXYIOCP-KBPBESRZSA-N (2s)-n-[2-[[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]amino]-2-oxoethyl]-5-oxopyrrolidine-2-carboxamide Chemical compound N([C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C(=O)CNC(=O)[C@@H]1CCC(=O)N1 DGYWXYFLXYIOCP-KBPBESRZSA-N 0.000 description 1
UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
ZCBIFHNDZBSCEP-UHFFFAOYSA-N 1H-indol-5-amine Chemical compound NC1=CC=C2NC=CC2=C1 ZCBIFHNDZBSCEP-UHFFFAOYSA-N 0.000 description 1
PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical group NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
XEWAGVYPFDNESQ-UHFFFAOYSA-N 3-pyrimidin-2-ylquinoline-2,8-diamine Chemical compound NC1=NC2=C(N)C=CC=C2C=C1C1=NC=CC=N1 XEWAGVYPFDNESQ-UHFFFAOYSA-N 0.000 description 1
108010007858 5-oxo-prolyl-glycyl-arginine-4-nitroanilide Proteins 0.000 description 1
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
102000012545 EGF-like domains Human genes 0.000 description 1
108050002150 EGF-like domains Proteins 0.000 description 1
241001131785 Escherichia coli HB101 Species 0.000 description 1
241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
LLKJHSDOKTVQNQ-IUCAKERBSA-N Glu-Gly-Arg-chloromethylketone Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(=O)CCl)CCCNC(N)=N LLKJHSDOKTVQNQ-IUCAKERBSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
208000033229 Immune-mediated cerebellar ataxia Diseases 0.000 description 1
101150045458 KEX2 gene Proteins 0.000 description 1
241000235058 Komagataella pastoris Species 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
102000016397 Methyltransferase Human genes 0.000 description 1
108060004795 Methyltransferase Proteins 0.000 description 1
MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
102000011931 Nucleoproteins Human genes 0.000 description 1
108010061100 Nucleoproteins Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
108010013639 Peptidoglycan Proteins 0.000 description 1
108090000279 Peptidyltransferases Proteins 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000012564 Q sepharose fast flow resin Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229960002684 aminocaproic acid Drugs 0.000 description 1
239000001166 ammonium sulphate Substances 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
230000002547 anomalous effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
239000003782 beta lactam antibiotic agent Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
229940126208 compound 22 Drugs 0.000 description 1
229940125877 compound 31 Drugs 0.000 description 1
229940125878 compound 36 Drugs 0.000 description 1
229940125807 compound 37 Drugs 0.000 description 1
229940126540 compound 41 Drugs 0.000 description 1
229940125936 compound 42 Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
238000000205 computational method Methods 0.000 description 1
238000005094 computer simulation Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
239000007819 coupling partner Substances 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
229940125808 covalent inhibitor Drugs 0.000 description 1
239000002577 cryoprotective agent Substances 0.000 description 1
238000012866 crystallographic experiment Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
108010004073 cysteinylcysteine Proteins 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000009509 drug development Methods 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
239000006167 equilibration buffer Substances 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960001031 glucose Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
239000007788 liquid Substances 0.000 description 1
RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
DFCXLPXOMCCXKM-UHFFFAOYSA-N phenylmethanesulfonic acid;hydrofluoride Chemical compound F.OS(=O)(=O)CC1=CC=CC=C1 DFCXLPXOMCCXKM-UHFFFAOYSA-N 0.000 description 1
ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical class [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000013014 purified material Substances 0.000 description 1
125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000523 sample Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000011896 sensitive detection Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
238000004088 simulation Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000005556 structure-activity relationship Methods 0.000 description 1
239000008362 succinate buffer Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000005469 synchrotron radiation Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
230000036964 tight binding Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
101150096103 vanX gene Proteins 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000002132 β-lactam antibiotic Substances 0.000 description 1
229940124586 β-lactam antibiotics Drugs 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/972—Plasminogen activators
- G01N2333/9723—Urokinase
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Physics & Mathematics (AREA)
Immunology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Bioinformatics & Computational Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Crystallography & Structural Chemistry (AREA)
Materials Engineering (AREA)
Metallurgy (AREA)
Organic Chemistry (AREA)
Analysing Materials By The Use Of Radiation (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

SK1324-2000A 1998-03-06 1999-03-05 Vyhľadávanie a návrh ligandov röntgenovou kryštalografiou SK13242000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US3618498A	1998-03-06	1998-03-06
PCT/US1999/004967 WO1999045379A2 (fr)	1998-03-06	1999-03-05	Criblage et elaboration de ligands par cristallographie aux rayons x

Publications (1)

Publication Number	Publication Date
SK13242000A3 true SK13242000A3 (sk)	2001-03-12

Family

ID=21887121

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1324-2000A SK13242000A3 (sk)	1998-03-06	1999-03-05	Vyhľadávanie a návrh ligandov röntgenovou kryštalografiou

Country Status (18)

Country	Link
US (1)	US6297021B1 (fr)
EP (1)	EP1068531B1 (fr)
JP (1)	JP2002506206A (fr)
KR (1)	KR20010041653A (fr)
CN (2)	CN100354627C (fr)
AT (1)	ATE375510T1 (fr)
AU (3)	AU2887099A (fr)
BG (1)	BG104802A (fr)
BR (1)	BR9908563A (fr)
CA (1)	CA2321968A1 (fr)
DE (1)	DE69937292T2 (fr)
HU (1)	HUP0101959A3 (fr)
IL (1)	IL137758A0 (fr)
NO (1)	NO20004433L (fr)
PL (1)	PL343264A1 (fr)
SK (1)	SK13242000A3 (fr)
TR (4)	TR200101127T2 (fr)
WO (2)	WO1999045389A2 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030049678A1 (en) *	1999-03-05	2003-03-13	Nienaber Vicki L.	Ligand screening and design by X-ray crystallography
US20030022383A1 (en) *	1999-04-06	2003-01-30	Uab Research Foundation	Method for screening crystallization conditions in solution crystal growth
US7247490B2 (en)	1999-04-06	2007-07-24	Uab Research Foundation	Method for screening crystallization conditions in solution crystal growth
US7214540B2 (en) *	1999-04-06	2007-05-08	Uab Research Foundation	Method for screening crystallization conditions in solution crystal growth
US7244396B2 (en)	1999-04-06	2007-07-17	Uab Research Foundation	Method for preparation of microarrays for screening of crystal growth conditions
US7250305B2 (en)	2001-07-30	2007-07-31	Uab Research Foundation	Use of dye to distinguish salt and protein crystals under microcrystallization conditions
US6630006B2 (en) *	1999-06-18	2003-10-07	The Regents Of The University Of California	Method for screening microcrystallizations for crystal formation
US20040252299A9 (en)	2000-01-07	2004-12-16	Lemmo Anthony V.	Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
US7108970B2 (en)	2000-01-07	2006-09-19	Transform Pharmaceuticals, Inc.	Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
GB0008563D0 (en)	2000-04-07	2000-05-24	Cambridge Discovery Chemistry	Investigating different physical and/or chemical forms of materials
WO2002022154A2 (fr) *	2000-09-13	2002-03-21	Praecis Pharmaceuticals Incorporated	Compositions pharmaceutiques pour medicaments a liberation prolongee
US7806980B2 (en)	2000-12-23	2010-10-05	Elan Pharmaceuticals, Inc.	Method for crystallizing human beta secretase in complex with an inhibitor
US7601528B1 (en)	2000-12-23	2009-10-13	Elan Pharmaceuticals, Inc.	Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease
US7217556B1 (en)	2000-12-23	2007-05-15	Pfizer Inc	Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease
US7670429B2 (en)	2001-04-05	2010-03-02	The California Institute Of Technology	High throughput screening of crystallization of materials
WO2002083938A2 (fr) *	2001-04-11	2002-10-24	Emerald Biostructures, Inc.	Procedes de criblage pour l'identification de ligands
US7384773B1 (en) *	2001-05-10	2008-06-10	Pfizer Inc	Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
US7524668B1 (en) *	2001-05-10	2009-04-28	Elan Pharmaceuticals, Inc.	Crystal of human beta secretase having monoclinic space group symmetry C2 and methods for crystallization thereof
US7130747B1 (en) *	2001-05-31	2006-10-31	Los Alamos National Security, Llc	High throughput screening of ligand binding to macromolecules using high resolution powder diffraction
IL151012A0 (en) *	2001-08-03	2003-02-12	Ribosomes Structure And Protei	Ribosomes structure and protein synthesis inhibitors
AU2002333508A1 (en) *	2001-08-22	2003-03-10	Novartis Ag	Method to identify modulators for human 3alpha-hydroxysteroid dehydrogenase
US20030211538A1 (en) *	2001-12-03	2003-11-13	Ming Luo	CAP-Gly domain structure and uses thereof
US20040171062A1 (en) *	2002-02-28	2004-09-02	Plexxikon, Inc.	Methods for the design of molecular scaffolds and ligands
US7469036B2 (en) *	2002-04-19	2008-12-23	Los Alamos National Security, Llc	Analysis of macromolecules, ligands and macromolecule-ligand complexes
US7442537B1 (en)	2002-05-10	2008-10-28	Elan Pharmaceuticals, Inc.	Crystals of unliganded beta secretase and/or beta secretase-like proteins and the use thereof
US6989392B2 (en) *	2002-06-18	2006-01-24	Abbott Laboratories	2-Aminoquinolines as melanin concentrating hormone receptor antagonists
US8019550B2 (en) *	2002-07-24	2011-09-13	Keddem Bioscience Ltd.	Drug discovery method
AU2003272548A1 (en) *	2002-09-16	2004-04-30	Plexxikon, Inc.	Crystal structure of pim-1 kinase
WO2006078228A1 (fr) *	2002-09-16	2006-07-27	Plexxikon, Inc.	Procedes de conception d'echafaudages moleculaires et de ligands
JP2006516095A (ja) *	2002-11-14	2006-06-22	ザスクリップスリサーチインスティテュート	脂肪酸アミドヒドロラーゼ（ｆａａｈ）の結晶形
ATE354096T1 (de) *	2002-12-23	2007-03-15	Astex Therapeutics Ltd	Synthese und screening von liganden mit hilfe von röntgenkristallographie
JP2007524374A (ja) *	2003-02-28	2007-08-30	プレキシコン，インコーポレーテッド	Ｐｙｋ２結晶構造および使用
WO2004092727A2 (fr) *	2003-04-11	2004-10-28	Structural Genomix, Inc.	Bibliotheques de composes et procedes de decouverte de medicaments
US20050079548A1 (en) *	2003-07-07	2005-04-14	Plexxikon, Inc.	Ligand development using PDE4B crystal structures
WO2005017533A1 (fr) *	2003-08-06	2005-02-24	Proteros Biostructures Gmbh	Procede d'identification de fragments moleculaires a faible pouvoir de liaison, aux proprietes de ligands, lesdits fragments moleculaires etant appliques sur un cristal, sous forme de microgouttes d'une solution appropriee
DE10336110B4 (de) *	2003-08-06	2008-01-03	Proteros Biostructures Gmbh	Vorrichtung und Verfahren zum Behandeln eines Proteinkristalls
WO2005028624A2 (fr) *	2003-09-15	2005-03-31	Plexxikon, Inc.	Echafaudages moleculaires pour le developpement de ligands des proteines kinases
DE10343522B4 (de) *	2003-09-19	2008-09-18	Proteros Biostructures Gmbh	Verfahren und Speichermedium zur Steuerung der Behandlung eines Kristalls mit einer Flüssigkeit
EP1899370A4 (fr) *	2005-05-12	2009-11-11	Cytopia Res Pty Ltd	Structure cristalline et son utilisation
US20090317850A1 (en) *	2008-06-20	2009-12-24	Tomoko Sunami	Crystal Structure of Human 70KD Ribosomal Protein S6 Kinase 1 Kinase Domain
CN101339167B (zh) *	2008-08-27	2011-12-14	中国药科大学	基于靶蛋白亲和选择的活性成分高通量筛选方法
DE102008049675A1 (de)	2008-09-30	2010-04-01	Markus Dr. Heinrich	Verfahren zur Herstellung von 3-Aminobiphenylen
WO2010100847A1 (fr) *	2009-03-03	2010-09-10	独立行政法人国立高等専門学校機構	Dispositif pour la cristallisation d'un biopolymère, cellule de solution pour la cristallisation d'un biopolymère, procédé pour le contrôle de l'alignement d'un biopolymère, procédé pour la cristallisation d'un biopolymère et cristal de biopolymère
CN102101886A (zh)	2009-12-18	2011-06-22	四川辉阳生命工程股份有限公司	构象改变的重组干扰素晶体、其三维结构及应用
JP5598238B2 (ja) *	2010-10-08	2014-10-01	株式会社リコー	画像形成装置
CN106033064B (zh) *	2015-03-10	2019-05-07	上海上药信谊药厂有限公司	胆维丁测定方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5112755A (en)	1982-04-15	1992-05-12	Genentech, Inc.	Preparation of functional human urokinase proteins

1999
- 1999-03-01 WO PCT/US1999/004518 patent/WO1999045389A2/fr not_active Ceased
- 1999-03-01 AU AU28870/99A patent/AU2887099A/en not_active Withdrawn
- 1999-03-05 CN CNB998058866A patent/CN100354627C/zh not_active Expired - Fee Related
- 1999-03-05 TR TR2001/01127T patent/TR200101127T2/xx unknown
- 1999-03-05 HU HU0101959A patent/HUP0101959A3/hu unknown
- 1999-03-05 TR TR2000/02572T patent/TR200002572T2/xx unknown
- 1999-03-05 DE DE69937292T patent/DE69937292T2/de not_active Expired - Fee Related
- 1999-03-05 TR TR2001/01129T patent/TR200101129T2/xx unknown
- 1999-03-05 SK SK1324-2000A patent/SK13242000A3/sk unknown
- 1999-03-05 JP JP2000534866A patent/JP2002506206A/ja active Pending
- 1999-03-05 BR BR9908563-1A patent/BR9908563A/pt not_active IP Right Cessation
- 1999-03-05 KR KR1020007009855A patent/KR20010041653A/ko not_active Withdrawn
- 1999-03-05 CN CN200710181713.2A patent/CN101221138A/zh active Pending
- 1999-03-05 AU AU29878/99A patent/AU767991B2/en not_active Ceased
- 1999-03-05 PL PL99343264A patent/PL343264A1/xx unknown
- 1999-03-05 AT AT99911174T patent/ATE375510T1/de not_active IP Right Cessation
- 1999-03-05 CA CA002321968A patent/CA2321968A1/fr not_active Abandoned
- 1999-03-05 US US09/263,904 patent/US6297021B1/en not_active Expired - Lifetime
- 1999-03-05 WO PCT/US1999/004967 patent/WO1999045379A2/fr not_active Ceased
- 1999-03-05 IL IL13775899A patent/IL137758A0/xx unknown
- 1999-03-05 EP EP99911174A patent/EP1068531B1/fr not_active Expired - Lifetime
- 1999-03-05 TR TR2001/01200T patent/TR200101200T2/xx unknown
2000
- 2000-09-05 NO NO20004433A patent/NO20004433L/no not_active Application Discontinuation
- 2000-09-27 BG BG104802A patent/BG104802A/bg unknown
2003
- 2003-10-16 AU AU2003255167A patent/AU2003255167A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TR200101129T2 (tr)	2002-06-21
CN100354627C (zh)	2007-12-12
AU2987899A (en)	1999-09-20
HUP0101959A3 (en)	2003-10-28
AU2003255167A1 (en)	2003-11-13
EP1068531A2 (fr)	2001-01-17
TR200002572T2 (tr)	2000-11-21
ATE375510T1 (de)	2007-10-15
IL137758A0 (en)	2001-10-31
DE69937292D1 (de)	2007-11-22
AU2887099A (en)	1999-09-20
WO1999045389A2 (fr)	1999-09-10
NO20004433L (no)	2000-11-06
WO1999045389A3 (fr)	2000-02-10
US6297021B1 (en)	2001-10-02
WO1999045379A3 (fr)	1999-11-25
JP2002506206A (ja)	2002-02-26
TR200101200T2 (tr)	2002-02-21
CN101221138A (zh)	2008-07-16
WO1999045379A2 (fr)	1999-09-10
NO20004433D0 (no)	2000-09-05
HUP0101959A2 (hu)	2001-09-28
TR200101127T2 (tr)	2002-06-21
EP1068531B1 (fr)	2007-10-10
BG104802A (bg)	2001-04-30
CA2321968A1 (fr)	1999-09-10
KR20010041653A (ko)	2001-05-25
CN1299467A (zh)	2001-06-13
DE69937292T2 (de)	2008-07-03
PL343264A1 (en)	2001-07-30
AU767991B2 (en)	2003-11-27
BR9908563A (pt)	2000-11-21

Publication	Publication Date	Title
SK13242000A3 (sk)	2001-03-12	Vyhľadávanie a návrh ligandov röntgenovou kryštalografiou
US6795776B1 (en)	2004-09-21	Crystallographic structure of the androgen receptor ligand binding domain
EP3353201B1 (fr)	2021-09-08	Chaînes lourdes de l'immunoglobuline recombinante comprenant une boucle de conjugaison par la sortase et leurs conjugués
Trenker et al.	2024	Structural dynamics of the active HER4 and HER2/HER4 complexes is finely tuned by different growth factors and glycosylation
US20040005686A1 (en)	2004-01-08	Crystalline structure of human MAPKAP kinase-2
US20040197893A1 (en)	2004-10-07	HDM2-inhibitor complexes and uses thereof
JP2012511333A (ja)	2012-05-24	グリカン特異的分析ツール
US20020034802A1 (en)	2002-03-21	Crystals of the alpha 1 beta 1 integrin I-domain and their use
Muller et al.	1998	Hinge bending within the cytokine receptor superfamily revealed by the 2.4 Å crystal structure of the extracellular domain of rabbit tissue factor
US20030049678A1 (en)	2003-03-13	Ligand screening and design by X-ray crystallography
WO2001040268A2 (fr)	2001-06-07	Analogues beryllofluorides de polypeptides de phosphate d'acyle
CZ20003246A3 (cs)	2001-03-14	Způsob vyhledávání a navrhování ligandů rentgenovou krystalografií
US20060036420A1 (en)	2006-02-16	Three-dimensional model of a complex between a Fc epsilon receptor alpha chain and a Fc region of an IgE antibody and uses thereof
CA2502647A1 (fr)	2004-04-29	Procedes de determination de structures cristallographiques par analyse des echanges d'hydrogene
MXPA00008696A (en)	2001-07-31	Ligand screening and design by x-ray crystallography
US20060014934A1 (en)	2006-01-19	Crystal structure of factor Vai and method for identifying blood factor Va modulators
Key	2025	Interactions of Integrin Mac-1 With Its Modulators
EP1743040B1 (fr)	2009-12-23	Complexes inhibiteurs hdm2 et utilisations de ceux-ci
CA2555684A1 (fr)	2005-08-18	Structures cristallines et modeles pour recepteurs fc et utilisations associees pour la conception et l'identification de composes modulateurs des recepteurs fc
AU2005210687A1 (en)	2005-08-18	Crystal structures and models for Fc receptors and uses thereof in the design or identification of Fc receptor modulator compounds
Influenza et al.	1990	Recognition at Membrane Surfaces